Overwatch Report

Eli Lilly and Company

January–April

[Economic Development and Industry] EU Pharmaceutical Strategy

Public Officials Lobbied

{'name': 'Seán Kelly', 'role': 'MEP (European Parliament)'} {'name': 'Deirdre Clune', 'role': 'MEP (European Parliament)'} {'name': 'Billy Kelleher', 'role': 'MEP (European Parliament)'} {'name': 'Barry Andrews', 'role': 'MEP (European Parliament)'}

Eli Lilly and Company

May–August

[Economic Development and Industry] EU Pharmaceutical Strategy

Public Officials Lobbied

{'name': 'Micheál Martin', 'role': 'An Taoiseach (Department of the Taoiseach)'}

Eli Lilly and Company

May–August

[Economic Development and Industry] EU Pharmaceutical Strategy

Public Officials Lobbied

{'name': 'Frances Fitzgerald', 'role': 'MEP (European Parliament)'}

Eli Lilly and Company

January–April

[Economic Development and Industry] Definition of "Essential Work" under the Covid-19 Regulations and Restrictions.

Public Officials Lobbied

{'name': 'Laura McGonigle', 'role': 'Special Adviser (Department of Foreign Affairs)'} {'name': 'Simon Coveney', 'role': 'Tánaiste and Minister (Department of Foreign Affairs)'} {'name': 'Heather Humphreys', 'role': 'Minister (Department of Business, Enterprise and Innovation)'} {'name': 'Michael McGrath', 'role': 'TD (Dáil Éireann, the Oireachtas)'}

Eli Lilly and Company

September–December

[Health] Update on clinical research and product development carried out by Eli Lilly and Company with respect to treatments for Covid-19

Public Officials Lobbied

{'name': 'Stephen Donnelly', 'role': 'Minister (Department of Health)'} {'name': 'Susan Mitchell', 'role': 'Special Adviser (Department of Health)'} {'name': 'Michael McGrath', 'role': 'Minister (Department of Public Expenditure and Reform)'} {'name': 'Laura McGonigle', 'role': 'Special Adviser (Department of Foreign Affairs)'}

Eli Lilly and Company

September–December

[Economic Development and Industry] Update on Eli Lilly Kinsale manufacturing and supply chain operations during the pandemic to date

Public Officials Lobbied

{'name': 'Leo Varadkar', 'role': 'An Tánaiste (Dáil Éireann, the Oireachtas)'}

Eli Lilly and Company

September–December

[Economic Development and Industry] Update on Lilly's business in Ireland, the opportunities and challenges for the biopharma sector in Ireland in the comings years - incl BREXIT; the need for investment in STEM education at all levels of the education system, and the importance a strong legislative framework for the protection of intellectual property rights in Ireland and at EU level.

Public Officials Lobbied

{'name': 'Jim Daly', 'role': 'Minister of State (Department of Health)'}

Eli Lilly and Company

September–December

[Transport] Discussions on safety and access improvements to roads around Lilly facilities in Kinsale and Little Island.

Public Officials Lobbied

{'name': 'Padraig Barrett', 'role': 'Director of Services or Equivalent (Cork County Council)'} {'name': 'Clodagh Henehan', 'role': 'Head of Directorate (Cork County Council)'} {'name': 'Michael William Lynch', 'role': 'Director of Services or Equivalent (Cork County Council)'}

Eli Lilly and Company

January–April

[Economic Development and Industry] Update on Lilly's business in Ireland, the opportunities and challenges facing the company and the pharma sector in the comings years - incl challenges of BREXIT; the need for investment in 3rd level and post-graduate education (specifically STEM subjects), to ensure continued supply of graduates & post-graduates to meet growing employment needs of the industry; outlined the importance of increased investment in road infrastructure in Kinsale/Dunderrow & Dunke

Public Officials Lobbied

{'name': 'Michael McGrath', 'role': 'TD (Dáil Éireann, the Oireachtas)'}

Eli Lilly and Company

January–April

[EU Affairs] EU Regulation REACh - Registration, Evaluation, Authorisation and Restriction of Chemicals

Public Officials Lobbied

{'name': 'Deirdre Clune', 'role': 'MEP (European Parliament)'} {'name': 'Seán Kelly', 'role': 'MEP (European Parliament)'} {'name': 'Mairead McGuinness', 'role': 'MEP (European Parliament)'}

Eli Lilly and Company

January–April

[EU Affairs] EU Regulation REACh - Registration, Evaluation, Authorisation and Restriction of Chemicals

Public Officials Lobbied

{'name': 'Nessa Childers', 'role': 'MEP (European Parliament)'} {'name': 'Lynn Boylan', 'role': 'MEP (European Parliament)'}

Eli Lilly and Company

May–August

[Economic Development and Industry] General update on Lilly's business in Ireland and Europe, the opportunities and challenges facing the company and the pharma sector in the next 5 years - incl challenges of BREXIT; the impact of European policy (across several policy areas) on the competitiveness of Europe and Ireland in competing for FDI globally. Also covered the importance of road infrastructure in Cork region, & investment in 3rd level education to ensure continued supply of graduates to m

Public Officials Lobbied

{'name': 'Deirdre Clune', 'role': 'MEP (European Parliament)'}

Eli Lilly and Company

September–December

[Transport] Investment in roads & transport infrastructure in Cork

Public Officials Lobbied

{'name': 'Clodagh Henehan', 'role': 'Director of Services or Equivalent (Cork County Council)'} {'name': "John O'Neill", 'role': 'Director of Services or Equivalent (Cork County Council)'}

Eli Lilly and Company

January–April

[Economic Development and Industry] Dr Lechleiter briefed Mr Callinan and Mr Kenny on Lilly's most recent investments in Ireland. The economic recovery was discussed as well as the current business environment generally for FDI in Ireland as it relates to companies such as Lilly. Dr Lechleiter reiterated the importance of "STEM" education at all levels of the Irish education system. He also outlined the importance of a sustained supply of high quality graduates to support the growth of Lilly's b

Public Officials Lobbied

{'name': 'John Callinan', 'role': 'Assistant Secretary (Department of the Taoiseach)'} {'name': 'Enda Kenny', 'role': 'TD (Dáil Éireann, the Oireachtas)'}

Eli Lilly and Company

January–April

[Economic Development and Industry] Dr Lechleiter briefed Mr Martin on Lilly's most recent investments in Ireland. The economic recovery was discussed as well as the current business environment generally for FDI in Ireland as it relates to companies such as LIlly . Dr Lechleiter also noted the importance of a supply of high quality graduates to support the continued growth of Lilly's businesses in Ireland

Public Officials Lobbied

{'name': 'Micheál Martin', 'role': 'TD (Dáil Éireann, the Oireachtas)'}

Lobbying Tracker

Most Lobbied TDs